0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-027
Home | Market Reports | Health | Health Conditions | Infectious Diseases
Hospital Acquired Methicillin Resistant Staphylococcus Aureus Epidemiology Forecast to 2028

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - Epidemiology Forecast to 2028

Code: DELV-Epid-027
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections outlook. It also includes the explanation of changing trends of epidemiology outlining the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections scenario.

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections

Key assessments
• Patient Segmentation in Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
• Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections Risk & Burden
• Factors driving growth in a specific Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections patient population

1. Report Introduction
2. Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 2016
2.2. Patient Share Distribution of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 2028
3. Disease Background and Overview: Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM
4.3. Total Prevalent/ Incident Patient Population of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM – By Countries
5. Epidemiology of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.1.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.1.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.1.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.4.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.4.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.4.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.5.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.5.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.5.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.6.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.6.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.6.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.7.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.7.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.7.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.8.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.8.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.8.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.9.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.9.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.9.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
6. Unmet Needs of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM
Table 2: Total Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)*
Table 6: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028)
Table 12: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028) *
Table 13: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028) *
Table 14: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028) *
Table 26: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM
Figure 2: Total Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028) *
Figure 14: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Accenture

RELATED REPORTS

Global Infectious Disease Diagnosis Market Size Status and Forecast 2021 2027
Global Infectious Disease Diagnosis Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10N1843
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Infectious Disease Diagnostics Testing Market Size Status and Forecast 2021 2027
Global Infectious Disease Diagnostics Testing Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Othe-2O272
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global HPV Associated Disorder Market Size Status and Forecast 2021 2027
Global HPV Associated Disorder Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-28G2646
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Hepatitis B Treatment Market Size Status and Forecast 2021 2027
Global Hepatitis B Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-34S2647
Sun Jul 18 00:00:00 UTC 2021

Add to Cart